We are live on ! Find out more
SPHS

Sophiris Bio, Inc.
SPHS

Delisted

SPHS was delisted on the 11th of March, 2020.

Back to rankings

18 hedge funds and large institutions have $14.3M invested in Sophiris Bio, Inc. in 2014 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 4 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

25% less funds holding

Funds holding: 24 → 18 (-6)

48% less capital invested

Capital invested by funds: $27.4M → $14.3M (-$13.1M)

75% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 4

86% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 7

Holders
18
Holders Change
-6
Holders Change %
-25%
% of All Funds
0.52%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
1
Reduced
4
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
GPP
Great Point Partners
Connecticut
+$253K
2
BIM
BlackRock Investment Management
Delaware
+$4.45K

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$4.77M
2
Franklin Resources
Franklin Resources
California
-$935K
3
First Manhattan
First Manhattan
New York
-$434K
4
Stifel Financial
Stifel Financial
Missouri
-$49K
5
BIM
Baldwin Investment Management
Pennsylvania
-$35K
Name Holding Trade Value Shares
Change 		Change in
Stake
T. Rowe Price Associates
1
T. Rowe Price Associates
Maryland
$3.61M -$2.66K -900 -0.1%
GPP
2
Great Point Partners
Connecticut
$3.55M +$253K +85,500 +6%
AG
3
Artal Group
Luxembourg
$2.24M – – –
First Manhattan
4
First Manhattan
New York
$1.35M -$434K -146,700 -20%
BI
5
BVF Inc
California
$1.34M – – –
PAI
6
Palo Alto Investors
California
$656K – – –
First Eagle Investment Management
7
First Eagle Investment Management
New York
$560K – – –
Franklin Resources
8
Franklin Resources
California
$412K -$935K -315,900 -63%
SC
9
Sophrosyne Capital
New York
$211K – – –
Deutsche Bank
10
Deutsche Bank
Germany
$165K – – –
TD Asset Management
11
TD Asset Management
Ontario, Canada
$132K – – –
Bank of New York Mellon
12
Bank of New York Mellon
New York
$28K – – –
Bank of Montreal
13
Bank of Montreal
Ontario, Canada
$3K – – –
BIM
14
BlackRock Investment Management
Delaware
$3K +$4.45K +1,503 New
Royal Bank of Canada
15
Royal Bank of Canada
Ontario, Canada
$2K – – –
Fidelity Investments
16
Fidelity Investments
Massachusetts
– -$4.77M -1,431,268 Closed
Stifel Financial
17
Stifel Financial
Missouri
– -$49K -14,825 Closed
BIM
18
Baldwin Investment Management
Pennsylvania
– -$35K -10,500 Closed
V
19
Veritable
Delaware
– -$35K -10,500 Closed
TRCT
20
Tower Research Capital (TRC)
New York
– -$5.53K -1,868 -95%
Citigroup
21
Citigroup
New York
– -$2K -588 Closed
AllianceBernstein
22
AllianceBernstein
Tennessee
– -$1K -383 Closed
U
23
UBS
Switzerland
– -$1K -312 Closed

SPHS Hedge Fund Activity: Q2 2014 in Review

18 of the 3,481 institutional investors tracked by Wall St. Rank reported a position in Sophiris Bio, Inc. (SPHS) for Q2 2014, worth a combined $14.3M — down 48% from $27.4M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of SPHS and 1 opened new positions — a net loss of 6 holders — while 4 trimmed existing stakes and 1 added.

The largest buyer was Great Point Partners, adding an estimated $253K. The largest seller was Fidelity Investments, exiting entirely with an estimated $4.77M sold.

  • 18 institutional investors held Sophiris Bio, Inc. (SPHS) as of Q2 2014, down from 24 in Q1 2014.
  • Funds reported $14.3M of Sophiris Bio, Inc. stock for Q2 2014, down 48% quarter-over-quarter.
  • 1 fund opened new Sophiris Bio, Inc. positions in Q2 2014 and 7 closed out, a net change of -6 holders.
  • The largest Sophiris Bio, Inc. buyer in Q2 2014 was Great Point Partners, an estimated $253K added.
  • The largest Sophiris Bio, Inc. seller in Q2 2014 was Fidelity Investments, an estimated $4.77M sold.

Based on aggregated 13F filings for Q2 2014.